Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel W Visscher

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
International Journal of Cancer|November 19, 2016
Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breastClara Bodelon, Hannah Oh, Nilanjan Chatterjee, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Breast Cancer Research and Treatment|June 26, 2016
Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissueHannah Oh, Clara Bodelon, Maya Palakal, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2013
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortiumMartin Köbel, Steve E Kalloger, Sandra Lee, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Breast Cancer Research and Treatment|April 17, 2016
Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypesKristen S Purrington, Daniel W Visscher, Chen Wang, et al.
Breast Cancer Research : BCR|December 8, 2017
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Journal of the National Cancer Institute|April 5, 2017
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerMatthew P Goetz, Krishna R Kalari, Vera J Suman, et al.
Breast Cancer Research and Treatment|August 23, 2015
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapyMarissa S Ellingson, Steven N Hart, Krishna R Kalari, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
International Journal of Cancer|November 19, 2016
Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breastClara Bodelon, Hannah Oh, Nilanjan Chatterjee, et al.
Human Molecular Genetics|April 11, 2013
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channelMine S Cicek, Devin C Koestler, Brooke L Fridley, et al.
Breast Cancer Research and Treatment|June 26, 2016
Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissueHannah Oh, Clara Bodelon, Maya Palakal, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond, Edith A Perez, John Bryant, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2013
Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortiumMartin Köbel, Steve E Kalloger, Sandra Lee, et al.
Gynecologic Oncology|January 29, 2019
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancerRachel M Hurley, Andrea E Wahner Hendrickson, Daniel W Visscher, et al.
Breast Cancer Research and Treatment|April 17, 2016
Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypesKristen S Purrington, Daniel W Visscher, Chen Wang, et al.
Breast Cancer Research : BCR|December 8, 2017
Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer studyJia Yu, Bo Qin, Ann M Moyer, et al.
Journal of the National Cancer Institute|April 5, 2017
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast CancerMatthew P Goetz, Krishna R Kalari, Vera J Suman, et al.
Breast Cancer Research and Treatment|August 23, 2015
Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapyMarissa S Ellingson, Steven N Hart, Krishna R Kalari, et al.
Pageof 13